Coya’s 120-patient ALS trial puts UAE drug access on 2027 watchlist

Coya Therapeutics is a speculative Buy for investors only if its 120-patient Phase 2 ALS trial reads out positively in Q1 2027, but for UAE operators the more practical question is whether the evidence can support future access, reimbursement and pharmacy handling.

The highest-stakes readers are medical directors, pharmacy leads and finance teams. Dubai providers regulated by the Dubai Health Authority (DHA) will need to track whether COYA 302 becomes a registered medicine or remains an investigational therapy. Abu Dhabi operators under the Department of Health Abu Dhabi (DOH), and northern emirates providers under the Ministry of Health and Prevention (MOHAP), face the same evidence question before any local prescribing pathway becomes routine.

What Streetwise reported

Streetwise Reports said its StreetSmart Research consensus gave Coya Therapeutics Inc. (NASDAQ: COYA) a Buy rating and an average target price of $15.63, equal to about AED 57.41 using the UAE dirham peg of AED 3.6725 per dollar. The cited analyst ratings ranged from $12 to $18. Coya shares were priced at $4.64 to $4.87 when the four ratings were issued, or roughly AED 17.04 to AED 17.89.

The company’s lead candidate, COYA 302, combines low-dose interleukin-2 with CTLA4-Ig. Coya says the therapy is designed to increase regulatory T-cell activity and reduce inflammatory immune activity in amyotrophic lateral sclerosis, or ALS. The drug remains investigational. The US Food and Drug Administration has granted Fast Track designation, according to Streetwise, but that status does not equal approval.

The core timetable is clear enough for UAE planning. ALSTARS is a 24-week, randomized, double-blind Phase 2 trial in adults with ALS at US and Canadian sites. Coya’s trial site lists 25 sites and says participants receive COYA 302 or placebo by subcutaneous injection for 5 consecutive days every other week, repeated in 4-week cycles for 24 weeks.

Why UAE clinics and insurers should care

ALS is a low-volume, high-cost neurology condition. A single new biologic can alter referral patterns, prior-authorisation workflows and patient expectations even before local launch. For Dubai clinics, the first checkpoint is the DHA setting for licensed prescribers and pharmacy operations. For Abu Dhabi, DOH rules govern facility practice, health insurance claims data and clinical research requirements. For Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain, MOHAP remains the relevant health authority for many provider settings, while the Emirates Drug Establishment (EDE) now provides the official UAE drug directory for registered medicines.

Finance teams should treat the Streetwise article as a catalyst watch, not a formulary signal. There is no UAE reimbursement price for COYA 302 today because it is still in Phase 2. To price current ALS medicine exposure, pharmacy and payer teams should check the EDE Drug Directory for registered products and request the registered medication price list through MOHAP where needed. Dubai essential-benefit coverage should also be checked against DHA’s applicable formulary and insurer rules before quoting a patient co-pay.

• Medical directors: watch the ALSFRS-R functional score in Q1 2027, since Streetwise cited analyst focus on a 2.0 to 2.5-point treatment effect over 24 weeks.
• CFOs: ask payers whether any future biologic would sit under pharmacy benefit, medical benefit, or exceptional approval.
• COOs: prepare an investigational-medicine checklist before accepting trial referrals or patient import requests.
• Pharmacy heads: verify cold-chain, injection training and dispensing authority before handling any biologic ALS therapy.

Access questions before 2027

Patients in the UAE will ask about access before regulators have a local answer. Clinics should give a narrow response: COYA 302 is in a North American trial, Coya says it does not currently offer an expanded access programme, and UAE use would require a lawful regulatory route. DHA, DOH and MOHAP-licensed providers should document counselling and avoid presenting analyst targets as clinical evidence.

Insurers such as Daman, Thiqa and Sukoon will need data on survival, function, safety, administration burden and total episode cost before making routine coverage decisions. The key documents to watch are Coya’s topline Phase 2 results in Q1 2027, any pivotal-trial plan in late 2027, and subsequent registration filings in the US or other reference markets.

For now, UAE operators should use the Coya story as a 2027 neurology watchlist item. Patients seeking licensed pharmacies for ALS medicines, cold-chain dispensing or insurer network checks can search the UAE Open Healthcare Directory for licensed pharmacy providers by emirate, regulator and insurance acceptance.